CD8A and brain neoplasm: BMs, in contrast to extracranial metastases, are generally considered to be relatively less sensitive to immunotherapy [12], mainly because the brain tumor microenvironment contains numerous myeloid cells, while the number and proportion of CD8+ effector T lymphocytes are rather limited [13].